Macular Degeneration Treatment Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Macular Degeneration Treatment Market Trends and Insights

Rising Prevalence of AMD in Aging Populations

Japan recorded 36.2 million citizens aged 65 and above in 2024, equal to 29.1% of its total population, while South Korea crossed the “super-aged” threshold at 20% in 2025. China expects 400 million people over 60 by 2030, and AMD incidence more than doubles with every decade after 60^{[1]Statistics Bureau of Japan, “Population Estimates 2024,” STAT, stat.go.jp}. Germany, Italy, and Spain each exceeded a 23% elderly share in 2025, driving double-digit growth in retina clinic visits. Because central-vision loss restricts daily living, governments fund AMD care even during economic downturns, shielding the macular degeneration treatment market from cyclical risk. These demographic realities create durable visibility into demand for at least the next two decades.

Rapid Expansion of Long-Acting Anti-VEGF Launches

Roche’s bispecific faricimab enabled 60% of trial participants to maintain 16-week intervals, halving the injection frequency compared with monthly aflibercept. Genentech’s Port Delivery System, a surgically implanted refillable ranibizumab reservoir, extends dosing to six-month intervals and received FDA clearance in 2024. Regeneron’s Eylea HD gained approval in 2024 with 8 mg strength that permits 12-16-week maintenance after loading. Extended durability reduces visit-related costs by USD 1,200-1,800 per patient annually in the United States. As durability improves, patient adherence climbs, and payers realize net savings, amplifying volume without proportional cost expansion in the macular degeneration treatment market.

Improved Ophthalmic Imaging & AI-Enabled Early Detection

Heidelberg Engineering integrated AI algorithms that automatically quantify drusen volume and pigmentary changes, reducing manual grading time by 80%. Topcon’s Harmony platform flags >10% annual drusen growth, directing high-risk patients toward complement-inhibition therapy. Japan mandated AI-OCT in annual municipal check-ups for seniors starting April 2025, boosting early-stage AMD diagnoses by 34% in pilot prefectures. Sensitivity and specificity above 89% enable prophylactic therapy before photoreceptor loss, expanding the funnel from diagnosed to treated in the macular degeneration treatment market. Earlier intervention lowers long-term disability costs and strengthens payer alignment with preventive care models

Biosimilar-Led Price Erosion Widening Access in Emerging Markets

Samsung Bioepis introduced SB11, a ranibizumab biosimilar, in the European Union at a 35% discount in January 2025, accelerating treatment volumes by 22% in Central and Eastern Europe. Formycon’s FYB203 entered 12 EU countries at 40% under originator pricing in September 2025, with Spain and Italy mandating substitution for naïve patients. In India, ranibizumab biosimilars cost INR 8,500 (USD 102) versus INR 28,000 for the branded product, increasing injection uptake by 47% in tier-2 cities. Brazil’s public health system added bevacizumab biosimilars to its formulary, expanding coverage to 2.3 million additional beneficiaries. These moves temper spending pressure and enlarge patient pools, buttressing revenue growth even as unit prices fall.

High Cost of Biologic and Gene Therapies

Originator anti-VEGF biologics list at USD 1,850-2,400 per dose in the United States, translating to USD 11,000-14,000 annually for monthly regimens. Gene-therapy candidates such as RGX-314 may launch at USD 600,000-750,000 per eye, echoing pricing precedents like Luxturna. In Brazil, one aflibercept injection equals 8.5 months of minimum-wage income, forcing legal action to secure public-sector supply. High upfront costs impede early intervention, causing patients to present later when therapy is less effective yet more expensive, thereby damping the macular degeneration treatment market growth potential^{[2]World Health Organization, “Global Report on Vision 2025,” WHO, who.int} .

Limited Reimbursement in Low-Income Regions

Many public health systems earmark less than 2% of their budgets for ophthalmology. Kenya’s insurance covers cataract surgery but excludes intravitreal biologics. The Philippines reimburses only 43% of the actual price of ranibizumab, deterring two-thirds of diagnosed patients from initiating treatment. Guatemala employs 47 retina specialists for 18 million people, concentrating services in the capital. Registration delays of 18-24 months for biosimilars prolong monopolies, keeping prices high and limiting market penetration of macular degeneration treatments.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Disease Form: Therapeutic Shift Toward Dry AMD

Wet AMD retained 69.58% of 2025 revenue, yet dry AMD is forecast to grow at an 9.48% CAGR as complement inhibitors secure commercial traction. The macular degeneration treatment market size for dry AMD is expected to widen rapidly once physicians gain confidence in lesion-growth reduction data. Monthly pegcetacoplan and avacincaptad pegol doses slowed geographic-atrophy expansion by up to 36%, a meaningful halt that supports premium reimbursement. Wet-form revenue is easing because biosimilar ranibizumab already accounts for 28% of European volume, and extended-interval aflibercept reduces vials per patient by 40% over three years^{[3]European Medicines Agency, “Ranibizumab Biosimilar SB11 Assessment Report,” EMA, ema.europa.eu}. 

Pipeline activity blurs categorical lines; up to 20% of dry AMD patients convert to neovascular disease, and combination trials are testing dual anti-VEGF plus complement blockade. Gene-therapy vectors encoding complement regulators, such as 4D-150, achieved early proof of concept with 68% vision stability at 12 months^{[4]4D Molecular Therapeutics, “Interim Data on 4D-150,” 4DMT, 4dmoleculartherapeutics.com} . As durable agents migrate from clinic to market, dry-form uptake will offset biosimilar erosion on the wet side, preserving overall macular degeneration treatment market momentum.

By Stage of Disease: Intermediate-Stage Prevention Is the Fastest-Rising Niche

Late-stage disease accounted for 57.53% of revenue in 2025 because neovascular cases require frequent anti-VEGF dosing, and geographic atrophy now has disease-modifying options. The macular degeneration treatment market share for early-stage remains modest, but intermediate-stage volume is climbing at an 7.63% CAGR on the back of AI-OCT triage and risk-based reimbursement approvals in Germany and the Netherlands. Extended detection widens the eligible cohort: over 3.2 million Americans have intermediate dry AMD but show no symptoms; payers now reimburse prophylactic complement inhibition for the top-risk quintile.

Adherence bottlenecks curb late-stage growth, as 58% of patients discontinue monthly anti-VEGF therapy within five years. In contrast, intermediate-stage patients often maintain better visual acuity and are more motivated to comply with less-frequent dosing. National screening in Japan identified 340,000 high-risk citizens in its first year, demonstrating that policy mandates can accelerate the growth of the macular degeneration treatment market for preventive therapy.

By Treatment Type: Devices Accelerate While Drugs Mature

Drugs accounted for 92.60% of 2025 spending, led by anti-VEGF agents whose biosimilar versions depress unit pricing while sustaining high volume. Complement inhibitors added USD 1.1 billion last year and will scale further as payers embrace their lesion-slowing benefit, although monthly dosing moderates persistence. Devices are the fastest-growing slice at an 8.75% CAGR, buoyed by Medicare coverage for electronic magnifiers and retinal implants that restore limited functional vision. 

The macular degeneration treatment market size for devices also benefits from the elderly's preference for non-invasive solutions once pharmacologic options plateau. Second Sight’s cortical implant entered limited European launch at USD 165,000 per unit, meeting pent-up demand among legally blind AMD patients. Telescopic contact lenses reached 18% penetration among eligible U.S. patients within 12 months, underscoring the willingness of patients to adopt wearable aids.

By Sales Channel: Online Pharmacy Emerges as High-Growth Outlet

Hospitals still accounted for 44.29% of 2025 revenue, as most biologics require cold-chain storage and on-site preparation under sterile conditions. Specialty and retail pharmacies manage oral nutraceuticals and some prefilled syringes, but online channels are booming at a 10.06% CAGR due to Amazon Pharmacy and CVS digital offerings that ship AREDS2 vitamins and low-vision aids within 48 hours. The macular degeneration treatment market share for online channels will continue rising as manufacturers develop room-temperature-stable anti-VEGF formulations that meet home-delivery regulations.

Alto Pharmacy’s AMD program bundled tele-optometry consults with automated refills, pushing adherence to 89% versus 62% for brick-and-mortar counterparts. Walgreens’ partnership with Notal Vision to rent home OCT units tightens the feedback loop between monitoring and drug shipment, illustrating how digital ecosystems can capture recurring revenue in the macular degeneration treatment market.

Geography Analysis

North America generated 49.43% of 2025 revenue, underpinned by Medicare Part B reimbursement that pays USD 650-850 per injection, including drug and professional fees Eylea HD obtained a USD 2,105 Part B payment rate in 2024, encouraging volume discounts and supporting steady procedure growth despite biosimilar entry. Canada covers ranibizumab and aflibercept under provincial formularies, yet faricimab access lags, leading patients to appeal through Exceptional Access Programs that add six-week delays. Mexico expanded coverage for ranibizumab biosimilars in 2025 through Seguro Popular, yet rural areas continue to experience specialist shortages that limit penetration.

Asia-Pacific is the fastest-growing region, advancing at a 10.34% CAGR. Japan reimburses up to 90% of biologic costs for seniors, with out-of-pocket caps of JPY 80,000 (USD 550) per month, driving high adherence. China added ranibizumab biosimilars to 15 provincial lists, trimming patient costs by 70% and expanding the market for macular degeneration treatments among urban workers. South Korea’s risk-sharing pact for faricimab caps annual expenses at KRW 12 million (USD 9,200), fuelling rapid uptake. India remains constrained; fewer than 20% of diagnosed patients initiate anti-VEGF therapy due to out-of-pocket costs exceeding INR 25,000 (USD 300) per injection.

Europe enjoys broad access, yet budgets are tight. Germany and France mandate biosimilar substitution for treatment-naïve cases, propelling 24% volume share for SB11 within 18 months. The United Kingdom negotiated confidential discounts that lowered per-injection spending by roughly 40%, adding 22% capacity without extra budget. Spain and Italy imposed monthly injection quotas in 2025, delaying therapy for 12-18% of patients and spurring legal challenges now pending before the European Court of Justice.

The Middle East and Africa remain nascent contributors. Saudi Arabia’s Vision 2030 plan earmarked SAR 800 million (USD 213 million) for 40 new retina clinics, improving geographic coverage. South Africa’s public sector does not reimburse anti-VEGF agents, limiting access to the privately insured 9 million residents. Latin America is mixed; Brazil’s public system adopted bevacizumab biosimilars, while Argentina’s economic turmoil and triple-digit inflation in 2024 disrupted imports of branded biologics.

Regulatory Landscape

Regulatory oversight for macular degeneration therapeutics is anchored by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Efficacy and ocular safety requirements for neovascular AMD are shaped by FDA guidance specific to drug development in this indication. In the United States, life-cycle changes that reduce injection burden are a key approval pathway, illustrated by the FDA approval in April 2026 extending EYLEA HD (aflibercept) dosing intervals up to 20 weeks for wet AMD and diabetic macular edema after a year of successful treatment. Formulation and presentation updates also move through streamlined label pathways, including the FDA approval in July 2024 for Genentech's Vabysmo prefilled syringe for retinal indications.

Biosimilar authorization in the United States and Europe continues to widen payer and provider options. The FDA approval of Sandoz's Enzeevu (aflibercept-abzv) came in August 2024, followed by EMA marketing authorisations for Baiama (January 2025) and Eyluxvi (September 2025) for aflibercept biosimilarity. In 2026, the EMA granted marketing authorisation for the ranibizumab biosimilar Ranluspec (February 2026), and the CHMP adopted a positive opinion for another ranibizumab biosimilar (Vislyfa) in May 2026. These steps reinforce the regulatory emphasis on comparability packages (analytical similarity and equivalent clinical performance) as a route to faster market entry. For differentiated biologics and repurposed ophthalmic formulations, timelines remain influenced by safety monitoring and complete-response cycles, reflected by the FDA acceptance in June 2026 of the resubmitted BLA for ONS-5010/LYTENAVA, with a PDUFA target action date of July 29, 2026.